首页 | 本学科首页   官方微博 | 高级检索  
     


Evaluation of the combination mode and features of p38 MAPK inhibitors: construction of different pharmacophore models and molecular docking
Authors:Bin Sun  Hong Zhang  Yue Dong  Liyu Zhao  Jun Han  Min Liu
Affiliation:1. Institute of BioPharmaceutical Research, Liaocheng University, Liaocheng, People’s Republic of China;2. Liaocheng People's Hospital, Liaocheng, People’s Republic of China;3. Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan, People’s Republic of China
Abstract:
Abnormal expression of tumour necrosis factor-α (TNF-α) can lead to various pathological reactions, such as arthritis, psoriasis, krone disease, etc. p38 mitogen-activated protein kinase (p38 MAPK) is an important signal transduction enzyme that plays important roles in influencing the release of intracellular TNF-α factor. It is very meaningful to study the targeting kinase with specific inhibitors in the treatment of related diseases. In order to achieve a deeper insight, it is necessary to analyse the structural characteristics and the action mode of the p38 MAPK inhibitors in the active site. In the study, a ligand-based common feature pharmacophore model and the receptor structure-based pharmacophore model were constructed, respectively. Their common chemical features consisted of the hydrophobic groups (H) and the hydrogen bond acceptors (A), and kept the consistency of spatial structure distribution. Then, the molecular docking and molecular dynamics simulation were performed with the eight training set compounds. The binding characteristics of molecules binding were described in the topological region of the active site. Finally, the structure–activity relationship (SAR) was obtained by analysing docking results with the different pharmacophore models. This research leads to the proposal of an interaction model in the p38 MAPK active site and provides guidance for the screening and design of more potent and selective p38 MAPK inhibitors.
Keywords:p38 MAPK inhibitors  targeting kinase  pharmacophore model  molecular docking
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号